| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Mizuho analyst Graig Suvannavejh maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and lowers the price target ...
Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target f...
TD Cowen analyst Phil Nadeau maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $50...
Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and raises the price target fro...
HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price...
Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly earnings of $1.67 per share which beat the analyst consensus estimate ...